Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 775 of 2051 entries
View as:

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

Phase: N/A Priority: Normal
NCT ID: NCT04456699 Org: User:
Start: 08/19/20 End: 11/06/23 Due: 11/06/24

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Phase: N/A Priority: Normal
NCT ID: NCT00836927 Org: User:
Start: 02/01/09 End: 02/04/18 Due: 02/04/19

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Phase: N/A Priority: Normal
NCT ID: NCT00692458 Org: User:
Start: 09/30/08 End: 09/30/08 Due: 09/30/09

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Phase: N/A Priority: Normal
NCT ID: NCT01047345 Org: User:
Start: 02/24/10 End: 11/28/15 Due: 11/28/16

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Phase: N/A Priority: Normal
NCT ID: NCT06492291 Org: User:
Start: 08/05/24 End: 10/13/28 Due: 10/13/29

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Phase: N/A Priority: Normal
NCT ID: NCT06814145 Org: User:
Start: 04/16/25 End: 03/30/29 Due: 03/30/30

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Phase: N/A Priority: Normal
NCT ID: NCT06780085 Org: User:
Start: 05/13/25 End: 03/12/32 Due: 03/12/33

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Phase: N/A Priority: Normal
NCT ID: NCT04305054 Org: User:
Start: 07/01/20 End: 04/03/30 Due: 04/03/31

A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)

Phase: N/A Priority: Normal
NCT ID: NCT00868790 Org: User:
Start: 03/24/09 End: 07/13/10 Due: 07/13/11

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Phase: N/A Priority: Normal
NCT ID: NCT06008756 Org: User:
Start: 10/09/23 End: 11/29/29 Due: 11/29/30

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Phase: N/A Priority: Normal
NCT ID: NCT06925737 Org: User:
Start: 05/13/25 End: 01/06/31 Due: 01/06/32

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Phase: N/A Priority: Normal
NCT ID: NCT01814748 Org: User:
Start: 05/03/13 End: 09/14/15 Due: 09/14/16

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Phase: N/A Priority: Normal
NCT ID: NCT00543595 Org: User:
Start: 08/31/04 End: 05/31/05 Due: 05/31/06

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Phase: N/A Priority: Normal
NCT ID: NCT02220894 Org: User:
Start: 10/30/14 End: 09/12/22 Due: 09/12/23

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092391 Org: User:
Start: 02/28/99 End: 07/31/01 Due: 07/31/02

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Phase: N/A Priority: Normal
NCT ID: NCT00701103 Org: User:
Start: 01/12/06 End: 12/01/09 Due: 12/01/10

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Phase: N/A Priority: Normal
NCT ID: NCT00251589 Org: User:
Start: 01/31/06 End: 10/31/07 Due: 10/31/08

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Phase: N/A Priority: Normal
NCT ID: NCT00511108 Org: User:
Start: 07/11/07 End: 02/24/09 Due: 02/24/10

A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)

Phase: N/A Priority: Normal
NCT ID: NCT00767793 Org: User:
Start: 09/30/08 End: 05/31/09 Due: 05/31/10

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Phase: N/A Priority: Normal
NCT ID: NCT01431521 Org: User:
Start: 10/26/11 End: 10/01/12 Due: 10/01/13

A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)

Phase: N/A Priority: Normal
NCT ID: NCT01193049 Org: User:
Start: 08/31/10 End: 05/31/11 Due: 05/31/12

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

Phase: N/A Priority: Normal
NCT ID: NCT00732641 Org: User:
Start: 12/31/00 End: 11/30/10 Due: 11/30/11

Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00050336 Org: User:
Start: 12/31/02 End: 03/31/04 Due: 03/31/05

Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

Phase: N/A Priority: Normal
NCT ID: NCT01852110 Org: User:
Start: 10/22/13 End: 04/11/16 Due: 04/11/17

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Phase: N/A Priority: Normal
NCT ID: NCT03873038 Org: User:
Start: 04/29/19 End: 12/20/21 Due: 12/20/22